KEGG   DRUG: Dolutegravir, abacavir and lamivudine
Entry
D10600            Mixture   Drug                                   
Name
Dolutegravir, abacavir and lamivudine;
Triumeq (TN)
Product
ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE (ViiV Healthcare Company)
Component
(Dolutegravir sodium [DR:D10113] | Dolutegravir [DR:D10066]), Abacavir sulfate [DR:D00891], Lamivudine [DR:D00353]
Class
Antiviral
 DG03107  Anti-HIV agent
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
 DG02924  UGT substrate
  DG03183  UGT1A1 substrate
Transporter inhibitor
 DG02863  SLC22A2 inhibitor
 DG02864  SLC47A1 inhibitor
Remark
Therapeutic category: 6250
ATC code: J05AR13
Product: D10600<JP/US>
Efficacy
Antiviral
  Disease
HIV-1 infection [DS:H01563]
Comment
Dolutegravir is metabolized by UGT1A1 with some contribution from CYP3A4.
Dolutegravir is an inhibitor of OCT2 and MATE1.
Target
HIV-1 reverse transcriptase [KO:K24802]
HIV-1 integrase [KO:K24803]
  Pathway
ko03230  Viral genome structure
ko03240  Viral replication
ko03250  Viral life cycle - HIV-1
Metabolism
Enzyme: UGT1A1 [HSA:54658]; CYP3A4 [HSA:1576]
Interaction
Transporter inhibition: SLC22A2 [HSA:6582], SLC47A1 [HSA:55244]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AR Antivirals for treatment of HIV infections, combinations
     J05AR13 Lamivudine, abacavir and dolutegravir
      D10600  Dolutegravir, abacavir and lamivudine <JP/US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-HIV Combinations
   Abacavir Sulfate/ Dolutegravir/ Lamivudine
    D10600  Dolutegravir, abacavir and lamivudine
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D10600  Dolutegravir, abacavir and lamivudine
Drug groups [BR:br08330]
 Antiviral
  DG03107  Anti-HIV agent
   D10600  Dolutegravir, abacavir and lamivudine
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D10600  Dolutegravir, abacavir and lamivudine
  DG02924  UGT substrate
   DG03183  UGT1A1 substrate
    D10600  Dolutegravir, abacavir and lamivudine
 Transporter inhibitor
  DG02863  SLC22A2 inhibitor
   D10600  Dolutegravir, abacavir and lamivudine
  DG02864  SLC47A1 inhibitor
   D10600  Dolutegravir, abacavir and lamivudine
Drug classes [BR:br08332]
 Antiviral
  DG03107  Anti-HIV agent
   D10600  Dolutegravir, abacavir and lamivudine
Antimicrobials [BR:br08307]
 Antivirals
  Genome replication inhibitor
   HIV integrase inhibitor
    D10600  Dolutegravir, abacavir and lamivudine <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10600
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10600
 Drug transporters
  D10600
Other DBs
PubChem: 254741562
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system